Stem Cell Transplant for Blood Cancer

This trial tests a new method for treating blood cancer using stem cell transplants. Researchers aim to determine if a combination of medicines, such as Treosulfan and Fludarabine, along with a special treatment to prevent complications, can benefit patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The trial seeks participants who have had these blood cancers and have a related or unrelated stem cell donor. Participants should have stable liver and kidney health and no serious heart issues. The trial aims to improve recovery and outcomes for those undergoing stem cell transplants. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to potentially groundbreaking advancements in blood cancer treatment.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

A previous study found that patients treated with treosulfan and fludarabine experienced positive safety outcomes. Research has shown that this combination usually carries a low risk of serious side effects, allowing most patients to tolerate it well. Importantly, this combination aids in the successful attachment and growth of donor cells, which is crucial for effective stem cell transplants. Additionally, no major safety concerns emerged that required special safety plans, known as REMS (Risk Evaluation and Mitigation Strategies), for treosulfan. This suggests that current research considers the treatment safe.¹²³⁴⁵

Researchers are excited about the treatment combining Fludarabine and Treosulfan for blood cancers like AML and MDS because it integrates a novel approach using PTCy as a graft-versus-host disease (GVHD) prophylaxis. Unlike standard conditioning regimens that often use busulfan or cyclophosphamide, this treatment uses Treosulfan, which may be less toxic and better tolerated. Additionally, post-transplant cyclophosphamide (PTCy) as part of the regimen may reduce the risk of GVHD more effectively than traditional methods. This combination could lead to improved outcomes and quality of life for patients undergoing stem cell transplants.

Research has shown that combining Treosulfan and Fludarabine is effective for patients with AML (acute myeloid leukemia) and MDS (myelodysplastic syndromes). In this trial, participants will receive the Treosulfan and Fludarabine preparative regimen with TBI, followed by a related or unrelated donor stem cell infusion. Studies have found that this combination leads to better outcomes than the traditional Busulfan-Fludarabine treatment. Specifically, one study reported that about 59.5% of patients experienced no major issues for 36 months. Additionally, this treatment is generally safer, causing fewer serious side effects while still allowing for successful donor cell integration. This makes it a promising option for patients undergoing stem cell transplants.⁶⁷⁸⁹¹⁰